Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children

N. Principi, P. Marchisio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7% of the patients treated with meropenem and in 95.3% of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2% in the meropenem group and 4.6% in the ceftazidime group. Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalJournal of Chemotherapy
Volume10
Issue number2
Publication statusPublished - 1998

Fingerprint

meropenem
Hospitalized Child
Ceftazidime
Infection
Therapeutics
Drug-Related Side Effects and Adverse Reactions

Keywords

  • Ceftazidime
  • Children
  • Empiric antibiotic treatment
  • Meropenem
  • Pediatric infections
  • Pediatric patients

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. / Principi, N.; Marchisio, P.

In: Journal of Chemotherapy, Vol. 10, No. 2, 1998, p. 108-113.

Research output: Contribution to journalArticle

@article{5a65703d985c4250bf0565d570c60398,
title = "Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children",
abstract = "In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7{\%} of the patients treated with meropenem and in 95.3{\%} of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2{\%} in the meropenem group and 4.6{\%} in the ceftazidime group. Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.",
keywords = "Ceftazidime, Children, Empiric antibiotic treatment, Meropenem, Pediatric infections, Pediatric patients",
author = "N. Principi and P. Marchisio",
year = "1998",
language = "English",
volume = "10",
pages = "108--113",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children

AU - Principi, N.

AU - Marchisio, P.

PY - 1998

Y1 - 1998

N2 - In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7% of the patients treated with meropenem and in 95.3% of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2% in the meropenem group and 4.6% in the ceftazidime group. Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.

AB - In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7% of the patients treated with meropenem and in 95.3% of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2% in the meropenem group and 4.6% in the ceftazidime group. Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.

KW - Ceftazidime

KW - Children

KW - Empiric antibiotic treatment

KW - Meropenem

KW - Pediatric infections

KW - Pediatric patients

UR - http://www.scopus.com/inward/record.url?scp=0031944025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031944025&partnerID=8YFLogxK

M3 - Article

C2 - 9603635

AN - SCOPUS:0031944025

VL - 10

SP - 108

EP - 113

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -